SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 13, 2000 LJL BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) 000-23647 (Commission File Number) DELAWARE 77-0360183 (State or other jurisdiction of (I.R.S. Employer Identification No.) incorporation) 405 TASMAN DRIVE SUNNYVALE, CA 94089 (Address of principal executive offices, with zip code) (408) 541-8787 (Registrant's telephone number, including area code) N/A (Former name or former address, if changed since last report) ITEM 5. OTHER EVENTS. On January 13, 2000, LJL BioSystems, Inc. announced expansion of its genomics platform with Informatics tools to enable automated SNP scoring and that Incyte Europe adopts LJL SNP Scoring Platform. Further details regarding this announcement are contained in the company's news release dated January 13, 2000 attached as an exhibit hereto and incorporated herein by reference. On January 13, 2000, LJL BioSystems, Inc discusses pivotal year and entry into genomics market at Chase Hambrecht & Quist conference. Further details regarding this announcement are contained in the company's news release dated January 13, 2000 attached as an exhibit hereto and incorporated herein by reference. ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS (a) Exhibits: 99.7 LJL BioSystems, Inc. News Release dated January 13, 2000 99.8 LJL BioSystems, Inc. News Release dated January 13, 2000 -2- SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LJL BIOSYSTEMS, INC. Date: January 13, 2000 By: /s/ LEV J. LEYTES ------------------------ Lev J. Leytes President and CEO -3-